Belite Bio to present Phase 3 DRAGON tinlarebant data at Retina China symposium
PUBT · 4d ago
Share
Listen to the news
- Belite Bio to deliver oral presentation at Retina China 2026 in Nanjing, China, May 21-23, 2026.
- Phase 3 DRAGON topline data on tinlarebant in Stargardt disease type 1 to be presented May 22, 2026, 1:54-2:02 p.m. CST.
- Company highlighted previously disclosed result showing 35.7% reduction in growth rate of atrophic retinal lesions versus placebo.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150800PRIMZONEFULLFEED9721089) on May 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved